Ronit Slotky, PhD, director, Cell Therapies Manufacturing Facility, Hackensack University Medical Center, discusses the evolving treatment landscape of stem cell transplants in multiple myeloma.
Stem cell transplants have been part of the treatment paradigm for patients with multiple myeloma for more than 20 years, Slotky says. Though other treatment regimens within multiple myeloma have emerged in recent years, the use of stem cell transplants has remained largely unchanged, Slotky explains.
Since the use of stem cells transplants has remained consistent since their inception, the improvement of other treatment options in multiple myeloma has benefited patient outcomes with a lower incidence of adverse effects, Slotky continues. These regimens now being given have allowed patients to live for a long time following diagnosis, Slotky concludes.